Project Grant R01HL172928
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $818,279 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on improving the subtyping and characterization of obstructive sleep apnea (OSA). The project will leverage data from existing research cohorts and a clinical biobank to quantify the reproducibility of OSA severity markers and derive physiologically...
- This $782,473 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to improve understanding of the pathogenesis of sleep apnea using novel imaging techniques during sleep. The project aims to characterize the site and pattern of airway collapse as well as how upper airway anatomy mediates this collapse, which could provide new insights to guide optimal therapies, particularly for patients who cannot tolerate...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to elucidate the complex relationship between obstructive sleep apnea (OSA) and cardiovascular disease (CVD). The $1,296,660 award supports a 24-month research project that will employ a "bed to bench" approach integrating clinical, computational, and in vitro techniques. Key objectives include developing and validating a mathematical model to quantify...
- This $464,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a research project titled "DIFFERENTIATING CHRONIC SLEEP DISRUPTION FROM INTERMITTENT HYPOXIA IN OSA ON TAU PATHOLOGY AND SPREAD" at the Icahn School of Medicine at Mount Sinai. The project aims to investigate the separate effects of chronic sleep disruption and intermittent hypoxia associated with obstructive sleep apnea (OSA) on the spread of tau pathology, a crucial step in...
- This federal Project Grant award of $449,861 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support a 24-month clinical observational feasibility study on dental practitioners' oral appliance therapy (OAT) titration methods and outcomes for patients with obstructive sleep apnea (OSA). The study will recruit 10 dental practitioners and 60 OSA patients (6 per practitioner) to examine practitioners'...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $583,718 Project Grant to Berendo Scientific LLC under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize and evaluate the SLEEPFLEX head and neck exercise program for the treatment of mild to moderate obstructive sleep apnea (OSA). The project aims to develop a focused, effective, safe, and non-invasive head and neck exercise program delivered via a smartphone app to increase the strength and endurance of key...
- The University of California, Los Angeles (UCLA) was awarded a $721,237 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the neural mechanisms by which inspiratory muscle training (IMT) can reduce blood pressure in patients with obstructive sleep apnea. The research project will use resting-state functional magnetic resonance imaging and magnetic resonance spectroscopy to assess changes in insula connectivity and...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $305,746 Project Grant under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) to Soliish, Inc. The award aims to develop a novel digital platform that uses deep learning to deliver a cost-effective, non-invasive, and user-friendly solution for early detection of obstructive sleep apnea (OSA). The solution, called OSANet, leverages analysis of oral cavity images to predict OSA risk and support...
- This Project Grant award, funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to study the impact of positive airway pressure (PAP) therapy on myocardial blood flow in adults with obstructive sleep apnea (OSA) at high risk of cardiovascular disease. The $173,556 award to Yale University will recruit 60 individuals with moderate PAP-naive OSA to test the hypotheses that OSA-specific measures of hypoxia and autonomic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nebraska Medical Center (UNMC) to evaluate a telehealth-delivered adaptive intervention for improving continuous positive airway pressure (CPAP) therapy adherence and health outcomes in adults with obstructive sleep apnea (OSA). The project aims to: 1) compare effects of motivational enhancement, device support, and...
TIME-RESOLVED MRI METHOD FOR EEG ASSISTED CONCURRENT MAPPING OF CEREBRAL OXYGEN METABOLISM AND AIRWAY STRUCTURE IN OBSTRUCTIVE SLEEP APNEA - PROJECT SUMMARY OBSTRUCTIVE SLEEP APNEA (OSA) IS THE MOST COMMON SLEEP DISORDER AND A RECOGNIZED RISK WITH AN ESTIMATED WORLDWIDE PREVALENCE OF ONE BILLION PEOPLE. THE ENSUING REPEATED EPISODES OF NOCTURNAL HYPOXIA AND HYPOXEMIA ARE AT THE CORE OF THE DISORDER'S PATHOGENESIS, LEADING TO UPREGULATION OF NEURO INFLAMMATION AND OXIDATIVE STRESS, WHICH PREDISPOSE OSA PATIENTS TO CARDIAC AND NEUROVASCULAR DISEASE ALONG WITH IMPAIRED COGNITIVE FUNCTION AND NEURODEGENERATION. THE INVESTIGATORS HAVE PREVIOUSLY EXAMINED THE NEUROVASCULAR-METABOLIC ALTERATIONS IN TERMS OF THE CEREBRAL METABOLIC RATE OF OXYGEN (CMRO2) AT REST AND IN RESPONSE TO APNEIC CHALLENGES DURING WAKEFULNESS IN THE FORM OF REPEATED CUED BREATH-HOLDS MIMICKING THE HYPERCAPNIC-HYPOXIC EVENTS OF SPONTANEOUS APNEA, BY MEANS OF TEMPORALLY-RESOLVED MRI-BASED BRAIN OXIMETRY. ALTHOUGH THIS WORK PROVIDED NEW INSIGHTS INTO CHRONIC AND ACUTE NEUROMETABOLIC CONSEQUENCES OF THE DISORDER, THE RESPONSE TO COACHED VOLITIONAL APNEAS LIKELY DIFFERS FROM THAT OF SPONTANEOUS APNEAS DURING SLEEP. ALSO UNKNOWN ARE THE UPPER AIRWAY'S MORPHOLOGIC CHANGES THAT OCCUR DURING APNEAS (FULL AIRWAY CLOSURE) AND HYPOPNEAS (PARTIAL CLOSURE) THAT CAUSE THE METABOLIC ALTERATIONS. LEADING UP TO THE PROPOSED PROJECT WE HAVE BEEN ABLE TO MONITOR CEREBRAL OXYGEN METABOLISM IN HEALTHY SUBJECTS IN THE SCANNER WITH CONCURRENT ELECTROENCEPHALOGRAPHY (EEG) AND DESIGNED AN IMAGING PROCEDURE THAT RETURNS THE VASCULAR-METABOLIC PARAMETERS AND UPPER AIRWAY MORPHOLOGY DURING CONTINUOUS SCANNING. WE ILLUSTRATE THE METHOD'S POTENTIAL WITH MODEL APNEAS INDUCED IN TEST SUBJECTS INVOLVING THE OROPHARYNGEAL PHASE OF SWALLOWING, CAUSING AIRWAY CLOSURE AND THE EXPECTED HYPOXIC-HYPERCAPNIC RESPONSE AND, MORE RECENTLY, IN A PATIENT WITH OSA DURING 90 MINUTES OF CONTINUOUS SCANNING AT SIX SECONDS TEMPORAL RESOLUTION DURING SLEEP IN THE SCANNER. THE KEY HYPOTHESIS UNDERLYING THE PROPOSED RESEARCH IS THAT THE METHOD CAN EVALUATE STATE-DEPENDENT O2 BRAIN METABOLISM AND AIRWAY ANATOMY IN OSA PATIENTS DURING WAKEFULNESS AND SLEEP AND DURING SPONTANEOUS APNEAS AND FURTHER, THAT THE ACUTE AIRWAY STRUCTURAL MANIFESTATIONS DURING APNEAS AND HYPOPNEAS CORRELATE WITH THE METABOLIC RESPONSE TO APNEAS. THE PROJECT COMPRISES THREE SPECIFIC AIMS: (1) OPTIMIZE THE TEMPORALLY RESOLVED INTERLEAVED STRUCTURAL AND METABOLIC MRI PROTOCOL AND SYNCHRONIZED AIRWAY PLETHYSMOGRAPHY TO CONFIRM THE METHOD'S ABILITY TO SIMULTANEOUSLY DETECT THE METABOLIC AND AIRWAY STRUCTURAL CHANGES DURING INDUCED APNEAS; (2) EXAMINE THE STATE DEPENDENCE OF O2 METABOLISM AND UPPER AIRWAY ANATOMY IN OSA PATIENTS DIFFERING IN DISEASE SEVERITY, WITH THE METHOD OF AIM 1 AND CONCURRENT EEG MONITORING; (3) EVALUATE THE HYPOTHESIS THAT THE TRANSIENT BRAIN METABOLIC AND UPPER AIRWAY CHANGES DURING APNEA CAN BE PREDICTED BY BASELINE MEASUREMENTS DURING RESPIRATION IN THE AWAKE STATE ALONG WITH THE SUBJECTS' BIOLOGICAL PROFILE OBTAINED FROM BLOOD MARKERS OF OXIDATIVE STRESS AND NEURO INFLAMMATION. THE PROPOSED RESEARCH SHOULD PROVIDE NEW INSIGHT INTO THE STRUCTURAL AND NEUROMETABOLIC IMPLICATIONS OF OSA AND THE DISORDER'S BIOLOGICAL UNDERPINNINGS, AND ULTIMATELY GUIDE THE DEVELOPMENT OF IMPROVED TREATMENT METHODS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $640.8k | 7/24/25 | ||
| Not listed | $0 | 10/22/24 | ||
| Not listed | $710.1k | 5/27/24 | ||
| Not listed | $710.1k | 5/27/24 |